Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 16

Results For "IDS"

417 News Found

dsm-firmenich to sell MEG-3 fish oil business to KD Pharma Group
News | July 22, 2024

dsm-firmenich to sell MEG-3 fish oil business to KD Pharma Group

dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business


Lupin’s partner ForDoz receives USFDA approval for doxorubicin hydrochloride liposome injection
Drug Approval | July 22, 2024

Lupin’s partner ForDoz receives USFDA approval for doxorubicin hydrochloride liposome injection

Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)


Increasing public awareness on World Zoonoses Day
News | July 08, 2024

Increasing public awareness on World Zoonoses Day

India boasts the largest livestock population, with 536 million livestock and 851 million poultry


Nephro Care India lists at 90% premium
News | July 06, 2024

Nephro Care India lists at 90% premium

NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90


Health Ministry issues advisory to states in view of zika virus cases from Maharashtra
Policy | July 04, 2024

Health Ministry issues advisory to states in view of zika virus cases from Maharashtra

States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika


MediPharm Labs acquires advanced medical cannabis delivery method technology from Remidose Aerosols
News | June 24, 2024

MediPharm Labs acquires advanced medical cannabis delivery method technology from Remidose Aerosols

Transaction is non-dilutive, with 100% performance-based payment through a royalty model


Gavi outlines plans to support access to new vaccines
News | June 09, 2024

Gavi outlines plans to support access to new vaccines

The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030


LVPEI raises awareness and funds for retinoblastoma treatment with WHITATHON Run
Healthcare | May 20, 2024

LVPEI raises awareness and funds for retinoblastoma treatment with WHITATHON Run

The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma


Ashland signs definitive agreement to sell nutraceuticals business to Turnspire Capital Partners
News | May 09, 2024

Ashland signs definitive agreement to sell nutraceuticals business to Turnspire Capital Partners

Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies